Welcome to ChemToo
📞 +86-0536-2205782 📧 arron.seagulls@gmail.com
Language: English | Japanese | Russian

2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide

CAS No.: 137-58-6

  • Molecular Formula: C14H22N2O
  • Molecular Weight: 234.34 g/mol

Chemical type

  • Amide-type local anesthetic
[1]
  • Amide local anesthetic
[2]

Key properties

  • Provides local anesthesia by blocking nerve signals
  • Concentration: 10 mg/ml
  • Administered volume: Up to 10 ml
[1]
  • Inhibits sodium ion channels on nerve cells and cardiomyocytes
  • Provides analgesic, anti-hyperalgesia, and anti-inflammatory effects
  • Stabilizes nerve cell membranes by inhibiting transmembrane sodium and potassium exchange
  • Reduces cerebral oxygen metabolism
  • Neuroprotective against neuroinflammation
[2]
  • Infiltrated into subcutaneous tissues, abdominal wall layers, and organ capsules during biopsy procedures
  • Reduces pain during skin puncture and needle advancement
[1]
  • Local anesthetic for surgery
  • Antiarrhythmic drug for acute ventricular tachycardia and premature ventricular beats
  • Perioperative intravenous infusion to reduce postoperative nausea, vomiting, and cognitive decline
  • Mitigates neuroinflammation and improves cerebral oxygen homeostasis in one-lung ventilation procedures
  • Administered as bolus (1.5 mg/kg) followed by continuous infusion (1.5 mg/kg/hr) during anesthesia
[2]

Classification by use

  • Chemicals used in medical anesthesia
  • Chemicals used in invasive procedures like biopsies
[1]
  • Anesthetics (local and general)
  • Antiarrhythmics
  • Analgesics and anti-inflammatory agents
  • Neuroprotective agents in surgery
[2]

A trustworthy factory and manufacturer

  1. [Cite:1] A core needle biopsy combined with novel spectroscopic probe for in vivo tissue classification – A pilot study on piglets, Biomedical Engineering Advances, Volume 10, November 2025, 100191
  2. [Cite:2] Lidocaine mitigates cognitive decline in elderly patients after video-assisted thoracoscopic surgery: A double-blind randomized controlled clinical trial, Brain Disorders, Volume 21, March 2026, 100308